Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration MALVERN, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...

CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical Development Program for Glioblastoma Multiforme LOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for...

CURE Pharmaceutical [OTCQB:CURR] Secures Patent on High Loading of Active Ingredient in Oral Thin Films OXNARD, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No....

Healthcare Tech Innovators Gofire Awarded U.S. Patent For Pioneering Precision-Dose ‘Smart Inhaler’ DENVER, May 29, 2019 (GLOBE NEWSWIRE) -- The United States Patent and Trademark Office (USPTO) has awarded healthcare technology leader Gofire™ its first patent for the company’s groundbreaking...

VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine More than 1,600 subjects enrolled in PROTECT studyTopline data expected mid-2019 CAMBRIDGE, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”) today announced...